- Home
- FOLD
as 11-21-2024 4:00pm EST
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | PRINCETON |
| Market Cap: | 2.8B | IPO Year: | 2007 |
| Target Price: | $17.57 | AVG Volume (30 days): | 2.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.35 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.02 - $14.57 | Next Earning Date: | 11-06-2024 |
| Revenue: | $493,671,000 | Revenue Growth: | 32.58% |
| Revenue Growth (this year): | 33.97% | Revenue Growth (next year): | 21.74% |
Stock Insider Trading Activity of Amicus Therapeutics Inc. (FOLD)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Campbell Bradley L | FOLD | President and CEO | Nov 6 '24 | Sell | $12.50 | 7,901 | $98,800.42 | 886,654 | |
| Campbell Bradley L | FOLD | President and CEO | Nov 1 '24 | Sell | $11.46 | 7,500 | $85,959.75 | 886,654 | |
| Campbell Bradley L | FOLD | President and CEO | Oct 1 '24 | Sell | $10.60 | 7,500 | $79,492.50 | 886,654 | |
| Campbell Bradley L | FOLD | President and CEO | Sep 3 '24 | Sell | $11.71 | 7,500 | $87,798.00 | 886,654 |
Latest Amicus Therapeutics Inc. News
FOLD Breaking Stock News: Dive into FOLD Ticker-Specific Updates for Smart Investing
Zacks
2 days ago
HALO vs. FOLD: Which Stock Should Value Investors Buy Now?
Simply Wall St.
13 days ago
Amicus Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Zacks
14 days ago
Amicus' Q3 Earnings & Revenues Beat Estimates, '24 View Updated
Zacks
14 days ago
Here's Why Amicus Therapeutics (FOLD) is a Strong Momentum Stock
GuruFocus.com
15 days ago
Amicus Therapeutics Inc (FOLD) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...
Thomson Reuters StreetEvents
15 days ago
Q3 2024 Amicus Therapeutics Inc Earnings Call
Zacks
15 days ago
Here's What Key Metrics Tell Us About Amicus Therapeutics (FOLD) Q3 Earnings
Zacks
15 days ago
Amicus Therapeutics (FOLD) Q3 Earnings and Revenues Beat Estimates
Compare FOLD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "FOLD Amicus Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.